Press Release Archive

Press Releases
Publications
Presentations

Press Releases Archive

12/08/15
Triphase Accelerator Corporation to Present Marizomib Clinical and Preclinical Data at Annual Meeting of the American Society of Hematology
11/19/15
Triphase Accelerator Corporation Announces FDA Orphan Drug Designation for Marizomib in Malignant Glioma
09/26/15
Triphase Accelerator Corporation Announces Phase 1 Study Results with Marizomib in Combination with Pomalidomide and Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma
09/25/15
Triphase Accelerator Corporation Announces Health Canada Approval to Initiate Marizomib Phase 1 Study in Recurrent Glioma Patients
04/22/15
Triphase Accelerator Corporation Initiates Phase I Study of Marizomib and Bevacizumab in Patients with Glioblastoma
02/26/15
Triphase Accelerator Corporation Enters into Academic Center Collaboration with Sunnybrook Research Institute to Advance Development of Bi-Specific Antibody in the Interest of Cancer Patients
12/06/14
Triphase Accelerator Corporation Announces Its Proteasome Inhibitor Marizomib Demonstrates Potent Synergistic Anti-Multiple Myeloma Activity
in Combination with Pomalidomide
10/28/14
Triphase Accelerator Corporation Announces New Collaboration with Celgene Corporation
10/28/14
Triphase Accelerator Corporation Announces Expanded Collaboration with Celgene Corporation
10/28/14
PharmAbcine Announces Global Licensing Deal with Triphase Accelerator Corporation for VEGFR-2/TIE 2 Bi-Specific Antibody
06/23/14
Triphase Accelerator Corporation Announces Orphan Drug Designation in the European Union for Marizomib for Multiple Myeloma
05/30/14
Triphase Accelerator Corporation Announces Preclinical Data on Proteasome Inhibitor Marizomib at 2014 ASCO Annual Meeting
02/27/14
Triphase Receives FDA Orphan Drug Designation for Marizomib in Multiple Myeloma
01/09/14
Triphase Signs Collaboration and Option Agreement with a Leading Innovator of Cancer Therapies, Celgene Corporation

View Latest Press Release